Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Almac and DSM Sign Collaboration Agreement in Biocatalysis

Almac
Posted on: 08 Oct 12

Almac is delighted to announce a collaboration agreement with Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.

The agreement grants both parties access to their enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients (APIs). Almac’s expertise in rapid enzyme identification, scale-up and implementation into early phase projects complements DSM’s experience and track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale. This will give customers of either party access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development from preclinical to commercial manufacturing scale. This collaboration will also enable Almac to offer its customers a preferred partner for large-scale production.

Alexander Wessels, CEO of DSM Pharmaceutical Products, stated, "Working with the Almac Group marks further advancement of DSM's stated strategy towards strategic partnerships to excel in providing new customer solutions. DSM is a global leader in applied biocatalysis, providing high quality custom manufacturing and development services to the pharmaceutical and biopharmaceutical industries. Via this agreement, we maintain our commitment to the future of pharma manufacturing, adding to our green chemistry toolbox, which also includes complex chemical solutions and more efficient manufacturing with micro reactors, where DSM is unique in its pilot to commercial scale up offering."

Dr. Tom Moody, Head of Almac Biocatalysis, stated “This collaboration has come at the right time as more and more customers need scalable green technologies to access difficult-to-make chiral chemicals. Having access to the right enzymes today will drive ‘hit to process’." The introduction of enzymes into processes earlier in the drug discovery pipeline will therefore help to drive cost down as the projects move forward”. Dr. Stephen Barr, Managing Director of Almac’s Sciences business unit, added, “The synergies between Almac and DSM are not superseded today by any other collaboration in this area. Our customers will see real rewards from the fact that any bioprocess developed can go from conception to manufacture quickly within this agreement.”

Daniel Mink PhD, Corporate Scientist Biocatalysis and (Bio)-Organic Chemistry at DSM comments:
"One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3,000 enzymes through in-house development as well as innovative partnering models. The collaboration with Almac completes the latest phase in this process. Together we will be able to offer a complete package serving the pharmaceutical industry at all stages of development from preclinical to commercial scale -- bringing biocatalysis to the next level.”

For more information:
http://www.almacgroup.com/

Editor's Details

Tristan Jervis
DeFacto
http://www.defacto.com/
+44 (0)207 861 3838
t.jervis@defacto.com

Last updated on: 08/10/2012

Advertising